Aptinyx’s NYX-2925 Draws Skepticism As It Fails Another Trial
The company is no longer pursuing development of the drug in painful diabetic peripheral neuropathy, but while more optimistic about fibromyalgia, that indication has less supporting data.
You may also be interested in...
Aptinyx Pulls Back From Neuropsychiatry After Mid-Stage PD Failure
The US firm has faced yet another clinical setback as its Phase II candidate, NYX-458, failed to improve cognitive impairment in patients with Parkinson’s disease and Alzheimer’s, triggering the cessation of its only other program as priorities shift to preserving funds.
Aptinyx Appears To Be Moving On From Pain With Fibromyalgia Miss
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.
Aptinyx To Forge Ahead With Pivotal PTSD Study
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.